Efficacy and Safety of Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution for Pediatric Wheezing Disorders in China: A Meta-Analysis and Evidence Mapping - Scorecard - DentalSpire
Advertisement
Efficacy and Safety of Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution for Pediatric Wheezing Disorders in China: A Meta-Analysis and Evidence Mapping
Clinical Scorecard: Efficacy and Safety of Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution for Pediatric Wheezing Disorders in China: A Meta-Analysis and Evidence Mapping
At a Glance
Category
Detail
Condition
Pediatric wheezing disorders
Key Mechanisms
Ambroxol enhances mucociliary clearance and has anti-inflammatory properties; Clenbuterol promotes bronchodilation.
Target Population
Children under 14 years with wheezing disorders including asthma, bronchiolitis, and wheezing bronchitis.
Care Setting
Clinical settings in China
Key Highlights
Combination therapy with AHCHOS significantly improved overall response rate and effective rate.
AHCHOS reduced duration of coughing, wheezing, cough phlegm, wet lung sounds, and hospital stay.
No increased risk of adverse events compared to conventional treatment.
Guideline-Based Recommendations
Diagnosis
Diagnosis of wheezing disorders should consider clinical history and symptomatology.
Management
Utilize bronchodilators, inhaled steroids, and AHCHOS as adjunctive therapy for symptom relief.
Monitoring & Follow-up
Monitor symptom resolution and length of hospital stay in pediatric patients.
Risks
Limited and inconsistent reporting of adverse events necessitates further safety assessments.
Patient & Prescribing Data
Children with wheezing disorders in China.
AHCHOS may provide modest improvements in symptom resolution without increasing adverse events.
Clinical Best Practices
Consider AHCHOS as an adjunctive therapy in managing pediatric wheezing disorders.
Tailor management strategies based on individual patient needs and severity of symptoms.
